Newswise — October 12, Schlieren, Switzerland— InSphero, the leading biotech for the development of complex 3D research disease models, announced the appointment of Prof. Francisco Verdeguer as the new Vice President, Head of the Liver Discovery Group where he will be focusing on metabolic diseases, especially NASH and associated disease models.
“Today, InSphero has the right strategy in place to successfully execute on its mission of improving the lives of people with some of the world’s most serious diseases, including NASH and diabetes,” commented Jan Lichtenberg, PhD, CEO of InSphero. “We are excited about the impressive metabolic disease experience Francisco brings to InSphero. Together with his talented scientific team, we will pursue our ambition to fuse 3D disease models reflecting patient diversity with deep-data generation and bioinformatics, for more efficient drug discovery.”
Verdeguer is an internationally recognized expert in the area of metabolic disorders and their underlying human biology. He began his career after receiving his PhD in molecular biology at the Pasteur Institute in Paris. Afterwards, at Harvard University/Dana Farber Cancer and Karolinska Institute, he focused on the molecular basis of metabolic disorders. In his most recent position as Assistant Professor at the University of Zurich, he led a research group and has identified novel transcriptional mechanisms of energy balance regulation.
Verdeguer commented "It is a privilege to contribute to InSphero's advanced in vitro technology and innovation, in pursuing my goal of enabling novel therapeutic strategies for metabolic disorders. I believe that synergistic collaborations of disruptive technology between companies like InSphero with pharmaceutical industry partners and leading academics, is the fastest and most promising path towards this enormous objective."
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats, and the Akura™ Flow organ-on-a-chip system, to drive efficient innovation throughout all phases of drug development.